Dr. Lee Sandquist, D.O. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 |
Alfred Higgins, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 |
Dr. Wesley Joseph Whitson, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 |
Mr. James Patrick Campbell, DO Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 |
Craig M Garver, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 |
Richard A Dickson, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 |
Peter Ward, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 |
Doniel Drazin, Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1201 S Miller St, Wenatchee, WA 98801 Phone: 509-663-8711 |
News Archive
Nathan Urban, interim provost and the Dr. Frederick A. Schwertz Distinguished Professor of Life Sciences, and Robert Kass, professor of statistics and machine learning, have received a $930,000 grant from the National Science Foundation to apply biological and statistical neuroscience approaches in order to create a better overall understanding of how neurons encode information.
Dr. Michal Kuczma, a research assistant professor in the Institute for Biomedical Sciences at Georgia State University, has received a three-year, $270,000 Career Development Award from the Crohn's and Colitis Foundation to study environmental influences on gut microbiota, immunity and inflammation.
A collaboration between experts and a Danish-based, global reaching patient organization has resulted in a groundbreaking medical publication, where guidelines are being presented on how to manage patients with unexplained low blood sugar.
Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the use of inhaled nitric oxide (iNO) with the INOpulse DS drug-delivery system as a combination product for pulmonary arterial hypertension.
› Verified 1 days ago